Source: Getty Images Investigators analyzed exfoliated cells in urine specimens to identify 50 candidate RNAs for prostate cancer detection. Serum PSA testing is not specific to prostate cancer, and ...

Prostate cancer is one of the most common and deadly forms of cancer in men, yet early detection remains a major challenge. That difficulty lies in how subtle the disease can be in its earliest stages ...

PSA testing and digital rectal exams are crucial for early detection of prostate cancer, enabling timely intervention and improved outcomes. Treatment options include active surveillance, surgery, ...

Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers ...

Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. To confirm the diagnosis, biopsies are required. A team of researchers has now ...

Fear of discomfort and unnecessary treatment often deters patients from prostate cancer screening, despite the benefits of early detection. Prostate cancer can be asymptomatic, making early detection ...

Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers ...

Dec. 15, 2025 — For decades, when tests suggested that a man might have prostate cancer, the next step was usually a biopsy. The procedure, where a doctor uses a thin needle to collect prostate ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Prostate cancer kills around 3,900 Australians a year.

Doctors began testing PSA levels in the 1980s to monitor diagnosed cancers. By the early 1990s, researchers promoted it for ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...